MARKET

LXRX

LXRX

Lexicon Pharmaceuticals Inc
NASDAQ
0.6900
-0.0234
-3.28%
After Hours: 0.6901 +0.0001 +0.01% 19:41 01/17 EST
OPEN
0.7203
PREV CLOSE
0.7134
HIGH
0.7203
LOW
0.6900
VOLUME
2.39M
TURNOVER
--
52 WEEK HIGH
3.730
52 WEEK LOW
0.6204
MARKET CAP
249.43M
P/E (TTM)
-0.9184
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LXRX last week (0106-0110)?
Weekly Report · 6d ago
Strong week for Lexicon Pharmaceuticals (NASDAQ:LXRX) shareholders doesn't alleviate pain of five-year loss
Simply Wall St · 01/07 12:28
Weekly Report: what happened at LXRX last week (1230-0103)?
Weekly Report · 01/06 09:23
Executive reshuffles: WELL, SLG and LXRX
Seeking Alpha · 01/04 20:54
Lexicon Pharmaceuticals Appoints New CFO Scott M. Coiante
TipRanks · 01/02 21:30
Lexicon Pharmaceuticals Names Scott Coiante Finance Chief
Dow Jones · 01/02 13:12
Press Release: Lexicon Appoints Scott Coiante as Chief Financial Officer
Dow Jones · 01/02 13:00
*Lexicon Appoints Scott Coiante as Chief Financial Officer >LXRX
Dow Jones · 01/02 13:00
More
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Webull offers Lexicon Pharmaceuticals Inc stock information, including NASDAQ: LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.